Cargando…

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma

BACKGROUND: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. METHODS: We used P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hee Sun, Lee, Da‐Hye, Kang, Da Hyun, Yeo, Min‐Kyung, Bae, Goeun, Lee, Dahye, Yoo, Geon, Kim, Ju‐Ock, Moon, Eunyoung, Huh, Yang Hoon, Lee, Sang‐Hee, Jo, Eun‐Kyeong, Cho, Sang Yeon, Lee, Jeong Eun, Chung, Chaeuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926029/ https://www.ncbi.nlm.nih.gov/pubmed/33486901 http://dx.doi.org/10.1002/cam4.3734

Ejemplares similares

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
por: Safaric Tepes, Polona, et al.
Publicado: (2021)

Dynamic changes in pathology and PD‐L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report
por: Hong, Green, et al.
Publicado: (2023)

Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma
por: Kim, Kyung-Hee, et al.
Publicado: (2019)

Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer
por: Lee, Sang Hoon, et al.
Publicado: (2020)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
por: Liu, Bailong, et al.
Publicado: (2021)

Epigenetic silencing of miR‐1271 enhances MEK1 and TEAD4 expression in gastric cancer
por: Lim, Byungho, et al.
Publicado: (2018)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines
por: Kim, Yong Joon, et al.
Publicado: (2020)

The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer
por: Yang, Xiao, et al.
Publicado: (2018)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Cloning and Sequence Analysis of the Nucleocapsid Gene of Porcine Epidemic Diarrhea Virus Chinju99
por: Lee, Hee-Kyung, et al.
Publicado: (2003)

Scientific Validation and Clinical Application of Lung Cancer Organoids
por: Lee, Dahye, et al.
Publicado: (2021)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
por: Bach, Duc-Hiep, et al.
Publicado: (2018)

Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation
por: Jang, Dahye, et al.
Publicado: (2018)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
por: Sun, Qi, et al.
Publicado: (2022)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
por: Cunningham, Richard, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
por: Kim, Tae-Jung, et al.
Publicado: (2017)

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma
por: Hwang, Hee Sang, et al.
Publicado: (2020)

Spontaneous regression of incidentally diagnosed bronchial squamous cell lung carcinoma after severe bronchitis: A case report
por: Kim, Yoonjoo, et al.
Publicado: (2021)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Early detection of delayed pneumothorax using lung ultrasound after transthoracic needle lung biopsy: A prospective pilot study
por: Koh, Jeong Suk, et al.
Publicado: (2022)

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status
por: Pak, Min Gyoung, et al.
Publicado: (2015)

YAP1 activation by human papillomavirus E7 promotes basal cell identity in squamous epithelia
por: Hatterschide, Joshua, et al.
Publicado: (2022)

Interferon‐induced transmembrane protein 1‐mediated EGFR/SOX2 signaling axis is essential for progression of non‐small cell lung cancer
por: Yang, Ying‐Gui, et al.
Publicado: (2018)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

EGFR-TKI不良反应管理专家共识
Publicado: (2019)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j3fctgt924vcc6682kta7vgufs